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Background: The hemagglutinin-neuraminidase (HN) protein is the major antigenic determinant of the Mumps
virus (MuV) and plays an important role in the viral infectious cycle through its hemagglutination/hemadsorption
(HA/HD) and neuraminidase (NA) activities. Objective: analyze the biological and immunological properties of a
polypeptide derived from a highly conserved region of the HN ectodomain. Methods: a highly conserved region of
the HN gene among several MuV genotypes was chosen to be cloned in a eukaryotic expression vector. The
pcDNAHN176-construct was transfected into Vero cells and RNA expression was detected by RT-PCR, while the
corresponding polypeptide was detected by immunofluorescence and immunochemistry techniques. The HD and
NA activities were also measured. The immunogenic properties of the construct were evaluated using two systems:
rabbit immunization to obtain sera for detection of the HN protein and neutralization of MuV infection, and
hamster immunization to evaluate protection against MuV infection.
Results: A 567 nucleotide region from the HN gene was amplified and cloned into the plasmid pcDNA3.1. Vero
cells transfected with the construct expressed a polypeptide that was recognized by a MuV-hyperimmune serum.
The construct-transfected cells showed HD and NA activities. Sera from immunized rabbits in vitro neutralized two
different MuV genotypes and also detected both the HN protein and the HN176 polypeptide by western blot.
Hamsters immunized with the pcDNAHN176-construct and challenged with MuV showed a mild viral infection in
comparison to non-immunized animals, and Th1 and Th2 cytokines were detected in them.
Conclusions: The pcDNAHN176-construct was capable of expressing a polypeptide in Vero cells that was identified
by a hyperimmune serum anti Mumps virus, and these cells showed the HD and NA activities of the complete
MuV HN protein. The construct also elicited a specific immune response against MuV infection in hamsters.
Background
Mumps is generally a childhood illness characterized by
parotid gland inflammation caused by the mumps virus
(MuV). The disease is usually mild, and approximately
one-third of MuV infections are asymptomatic. How-
ever, up to 10% of patients may develop aseptic menin-
g i t i sa n do t h e rl e s sf r e q u e n t ,b u tm o r es e r i o u s ,
complications, such as encephalitis, deafness, orchitis
and pancreatitis, which can result in permanent disabil-
ity. In fact, mumps encephalitis accounted for 36% of
the total viral encephalitis cases before introduction of
the MuV vaccine [1-7]. It has been accepted that MuV
is a monotypic virus [8]. However, this assumption has
been challenged due to the recent resurgence of mumps
epidemics in many countries with ongoing vaccination
programs [9-13], the presence of several mumps reinfec-
tion cases [14], along with the evidence of distinct
lineages of MuV co-circulating globally [6,11,13,15-20].
Currently, thirteen MuV genotypes (A to M) have been
* Correspondence: bbarron@ipn.mx
† Contributed equally
1Lab Virología, ENCB-IPN Carpio y Plan de Ayala S/N Casco de Santo Tomás,
México D.F. 11340 México
Full list of author information is available at the end of the article
Herrera et al. Virology Journal 2010, 7:195
http://www.virologyj.com/content/7/1/195
© 2010 Herrera et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.defined on the basis of the nucleotide sequence of the
MuV SH gene [6,10,21]. Furthermore, two important
mumps outbreaks were recently reported, one in 2005
in the UK, and the other in 2006 in the USA. In both
cases, the G MuV genotype was identified, even though
both countries have been using the mumps Jeryl Lynn
vaccine, which has been identified as an A genotype
[5,6,22].
MuV is a member of the genus Rubulavirus of the
Paramyxoviridae Family. Its genome is a single-
stranded, negative sense, non-segmented RNA of 15,384
nucleotides. The genome encodes for three nucleocap-
sid-associated proteins: an RNA binding protein (N), a
phosphoprotein (P) and a large polymerase protein (L),
four membrane proteins, an unglycosylated inner mem-
brane or matrix protein (M) and three glycosylated
envelope proteins, the fusion protein (F), the hemagglu-
tinin-neuraminidase (HN) protein and the small hydro-
phobic protein (SH) [23].
HN is the major antigenic protein known to elicit
neutralizing antibodies [23]. It also plays an important
role in the viral infectious cycle. It is the viral attach-
ment protein for host cell receptors (sialylated glycocon-
jugates), enhances the fusogenic activity of the viral F
protein to allow viral entry into the cell, and its sialidase
activity hydrolyzes sialic acid residues to prevent virus
self-aggregation, facilitating viral spread of the new vir-
ions [24].
The crucial role played by the HN protein in the host
protective immune response against MuV infections
makes this protein a good target to develop a vaccine
that might be useful against most of the MuV genotypes.
Therefore, the aim of this paper was to look for a highly
conserved and immunogenic region of the HN protein
among different mumps virus genotypes and express the
corresponding polypeptide. By in silico analyses, a highly
conserved region of the HN gene among different MuV
genotypes was found and this paper describes construc-
tion of the DNA recombinant vector and biological char-
acterization of the expressed polypeptide.
Results
Characterization of the pcDNAHN176-construct
The PCR amplification of the pcDNAHN176-construct
using the set of HN primers initially designed produced
a 580-bp fragment, which corresponded to the expected
size of the HN insert (Figure 1A, lane 3). Enzymatic
restriction of the pcDNAHN176-construct released a
567-bp fragment, which was the size of the HN gene
fragment previously cloned (Figure 1B, lane 5). Sequen-
cing of the HN gene fragment indicated that the insert
could encode for a 176 amino acid polypeptide (aa 255-
431) that shared a 97.3% similarity with the Urabe HN
protein (data not shown).
Expression of the HN176 fragment in Vero transformed
cells
The RNA-HN176 expression was analyzed by RT-PCR
using total RNA extracted from pcDNAHN176-trans-
fected Vero cells. A 580-bp specific band (Figure 2A,
lane 6) that corresponded to the expected size of HN
insert was detected. No amplification was obtained from
untransfected Vero cells or from cells transfected with
the pcDNA3.1 vector (Figure 2A, lanes 4 and 5). To ver-
ify that the 580 bp amplicon obtained from
pcDNAHN176-transfected cells was not due to an
amplification of the DNA construct, total RNA was
directly used as a template for PCR, and no amplifica-
tion was observed (Figure 2B, lane 2).
The expression of HN polypeptide was evaluated by
immunochemistry and immunofluorescence assays using
a hyperimmune anti-MuV serum. Both assays showed
that the pcDNAHN176-transfected cells reacted with
the anti-MuV serum, even though their reactivity was
lower compared to MuV-infected cells (Figure 2C).
Biological activities of the HN176 polypeptide
To analyze if the expressed HN176 polypeptide
retained the main biological activities of the complete
HN protein, the hemagglutinin property was evaluated
by a hemadsorption (HD) reaction with sialic acid
receptors present on red cell membranes [25]. MuV-
infected cells showed an HD reaction characterized by
the presence of clumps of red cells on them (Figure
3Ab), while no reactivity was found in pcDNA3.1-
transfected cells (Figure 3Ac) or mock-infected cells
(Figure 3Aa). In contrast, an HD reaction was also
observed in the pcDNAHN176-transfected cells,
although the intensity of the HD reaction was lower
than in MuV-infected cells, but the erythrocytes were
clearly observed (Figure 3Ad). To verify the specificity
of the HD reaction, the amount of red cells adsorbed
to the cells was measured using the quantitative colori-
metric determination of hemoglobin concentration
according to the method described by Drabkin, 1935
[26]. No hemoglobin was detected in pcDNA3.1-trans-
fected cells or mock-infected cells, but the
pcDNAHN176-transfected cells (Figure 3C) showed
40% of the hemoglobin concentration in comparison
with the hemoglobin detected in MuV-infected cells.
Furthermore, the HD reaction was not observed in
MuV-infected Vero cells or in the pcDNAHN176-
transfected cells when a hyperimmune anti-MuV
serum was used, supporting the specificity of the HD
reaction (data not shown).
To analyze if the HN176 polypeptide also had a
neuraminidase activity (NA), total protein extracts
obtained from pcDNAHN176-transfected cells and
from MuV-infected cells were tested by a dot and
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N-acetylneuraminic acid (MU-NANA) as a substrate.
Both cellular extracts displayed neuraminidase activity
(Figures. 3B and 3D); however, the NA activity in the
pcDNAHN176-transfected cells was lower, 38.93% and
24.4% by dot and spectrophotometric methods, respec-
tively, compared to the NA activity in the MuV-infected
cells.
All of these results indicated that the pcDNAHN176-
transfected cells presented both activities, HD and NA,
of the HN MuV complete protein.
Immunogenic properties of the HN 176 polypeptide
Rabbit’s sera
Sera obtained from rabbits immunized with the
pcDNAHN176-construct had a 50% titer of neutralizing
Figure 1 Characterization of the pcDNAHN176-construct by PCR and enzymatic restriction. A) PCR amplification of the insert using the
HN primers. Lane 1) jX174 DNA-HaeIII marker; Lane 2) Negative control; Lane 3) pcDNA-HN176. The arrow indicates the amplicon of 580 bp. 1%
agarose gel/100 V/1 hr/49 mA. B) Enzymatic restriction with Bam HI and KpnI to release the HN176 insert. Lane 1) l Hind III marker; Lane 2)
Unrestricted pcDNA3.1; Lane 3) Restricted pcDNA3.1; Lane 4) Unrestricted pcDNA-HN176; Lane 5) restricted pcDNA-HN176, Lane 6) jX174 DNA-
HaeIII marker. The arrow indicates the insertion of 567 bp. 1% agarose gel/100 V/1 hr/45 mA
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3.75 for both the Urabe and Jeryl Lynn
MuV strains (Table 1). Furthermore, western blot analy-
sis confirmed that the sera from rabbits immunized with
the construct were able to recognize the complete 58
KDa viral HN protein, and also the 20.4 KDa polypep-
tide expressed by the pcDNAHN176-transfected cells
(Figure 4A lanes 4 and 5). These assays showed that
pcDNAHN176-immunization induced an immune
response that recognized the complete HN protein and
neutralized MuV infection.
Hamster protection
Figure 4 presents the body weight gain after MuV chal-
lenge in the six hamsters groups. It is clearly shown that
the non-immunized (group B) or the pcDNA3.1-immu-
nized (group E) animals experienced a mean weight loss
of 5-20% of their original body weight 4-7 days after
MuV challenge. On the contrary, the pcDNAHN176-
immunized group (F) gained body weight compared
with the non-challenged groups (A, C, D). To confirm
MuV infection in the challenged groups, several organs
were removed and used for MuV isolation in Vero cells,
and the virus was detected by HD reaction. MuV was
isolated from all three challenged groups (B, E, and F).
Trachea, lung, liver, pancreas, sexual gonads and brain
from the viral control group (B) and group G were posi-
tive for MuV isolation; in contrast, only the liver and
brain from the pcDNAHN176-immunized group (F)
were positive for viral isolation (Figure 5C).
In all of the animal groups challenged with MuV
(B, E, F), neutralizing antibodies against MuV were
detected, and in all of them, the titers were similar
(Table 1). DNA immunization with the pcDNAHN176-
c o n s t r u c t( g r o u pD )i n d u c e dneutralization antibodies,
but the titer was low, and after viral challenge, the titer
Figure 2 Expression of the pcDNAHN176-construct. A) Detection of HN176 mRNA in transfected Vero cells by RT-PCR amplification. Lane 1)
jX174 DNA-HaeIII marker; Lane 2) RT/PCR negative control; Lane 3) Positive control (MuV-infected cells); Lane 4) Vero-untransfected cells, 5) Vero
cells transfected with the plasmid pcDNA3.1, Lane 6) Vero cells transfected with the pcDNA-HN176-construct. The arrow indicates 580 bp
amplicon. 1% agarose gel/100 V/1 hr/49 mA. B) RT-PCR Controls. Lane 1) jX174 DNA-HaeIII marker; Lane 2) PCR amplification of the RNA
samples obtained from pcDNAHN176-transfected Vero cells without a previous RT reaction; Lane 3 and 4) RT/PCR amplification of b-actin gene
using RNA samples obtained from HeLa cells and pcDNAHN176-transfected Vero cells, respectively. C) Immunodetection of the HN176
polypeptide by immunochemistry (1
st row) and immunofluorescence (2
nd row). Frames 1 & 5 mock infected cells; 2 & 6 pcDNA3.1-transfected
cells; 3 & 7 MuV-infected cells; 4 & 8 pcDNAHN176-transfected cells, the blue (immunochemistry) and the green (immunofluorescence) colors
indicate a positive reaction, N indicates the nucleus. 40×
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control group (B).
The lymphoproliferation assay (Figure 4F) showed that
the group immunized with the pcDNAHN176-construct
(Group D) induced a higher and specific response
against MuV compared to the pcDNA3.1-immunized
group (C), whose response to MuV was lower than the
response to the PHA mitogen. However, the lympho-
proliferative response to MuV in group F (construct
immunized/MuV challenged) was similar to the
response found in group B (viral control group), indicat-
ing that MuV infection induced a certain level of speci-
fic lymphoproliferative response, which was not
increased, even in animals that were immunized before
viral infection.
Cytokines like IFNg were detected only in the
pcDNA3.1- or pcDNAHN176-immunized/challenged
groups (E, F), and in both groups, the IFNg
Figure 3 Hemadsorption and neuraminidase activities in the pcDNAHN176 transfected cells. A). Hemadsorption (HD) reaction. a) Mock
infected cells; b) MuV-infected cells; c) pcDNA-3.1-transfected cells; d) pcDNAHN176-transfected Vero cells. The red cell aggregates indicate a
positive HD. 40×. B) Neuraminidase (NA) reaction in total cellular protein extract by a dot blot assay: a) Mock infected cells; b) MuV-infected cells;
c) pcDNA-3.1-transfected cells; d) pcDNAHN176-transfected Vero cells. C) % of hemoglobin (Hb) released after the HD. The Hb absorbance of
MuV-infected cells was considered as 100% and was used to calculate the % of Hb for the different cells. D) Comparison of the NA activity in
MuV-infected cells, pcDNA3.1-transfected cells and pcDNAHN176-transfected Vero cells by dot blot and spectrophotometric methods.
Table 1 Titer of neutralizing antibodies against MuV *




























*Expressed as the reciprocal of the highest serum dilution that protects 50% of the inoculated cell cultures.
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I L4w e r ed e t e c t e di na l lo ft h eg r o u p s ,b u to n l yI L5
was detected in group F (Figure 4E). All of these results
suggested that pcDNAHN176-immunized animals were
capable of responding to MuV infection by inducing
both the Th1 and Th2 immune specific responses and
probably secretion of IgA in the mucosa.
Discussion
MuV HN protein is a highly relevant protein in the viral
infectious cycle. It is responsible for viral interaction
with cellular receptors and, in fact, is the main viral
antigenic determinant [23]. In this paper, a highly con-
served and immunogenic region of the MuV HN gene
was chosen for cloning based on our bioinformatics ana-
lysis carried out with several MuV genotypes. The
region was located from 817 to 1383 nucleotides in the
Urabe MuV strain, which potentially encodes a 176 aa
polypeptide (HN176) corresponding to the amino acid
positions 255 to 431 of the HN protein.
After cloning the HN region in the eukaryotic expres-
sion vector pcDNA3.1, which is commonly used for
high-level stable expression in mammalian cells [27-30],
i t se x p r e s s i o nw a sa n a l y z e di n Vero-transfected cells.
Figure 4 Immunological properties of the pcDNAHN176-construct. A) Detection of the HN176 polypeptide and HN protein by Western Blot.
Lane 1) Negative control, uninfected cells and sera from pcDNAHN176-immunized rabbits; Lane 2) MuV-infected-Vero cells and anti-MuV serum;
Lane 3) pcDNAHN176-transfected cells and anti-MuV serum; Lane 4) MuV-infected-Vero cells and sera from pcDNAHN176-immunized rabbits;
Lane 5) pcDNAHN176-transfected cells and sera from pcDNAHN176-immunized rabbits. The upper arrow indicates in lane 2 and 4 the position
of the complete viral HN protein, and the lower arrow indicates the position of the HN176 polypeptide in lanes 3 & 5. B) Body gain weight of
hamsters immunized and challenged with MuV. Group A, animals without immunization and uninfected; Group B, viral control group (animals
without immunization and challenged with MuV); Group C, animals immunized with pcDNA3.1 without challenge; Group D, animals immunized
with pcDNAHN176-construct without challenge; Group E, animals immunized with pcDNA3.1 and challenged with MuV; Group F, animals
immunized with pcDNAHN176 and challenged with MuV. C) Virus isolation from different organs of the hamsters groups. MuV was detected by
HD, quantifying the amount of Hb. D) Detection of IL associated to Th1 response in the hamsters groups. E) Detection of IL associated to Th2
response in the hamsters groups. ILs were measured using the Luminex System (Invitrogen ®). F) Lymphoproliferation index of spleen cells
obtained from the hamsters groups. Cell proliferation was measured by MTT method.
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expressed the corresponding RNA and polypeptide. The
HN176 polypeptide was demonstrated by immunochem-
istry and immunofluorescence methods using a refer-
ence hyperimmune serum anti-MuV, indicating that at
least one of the antigenic HN epitopes previously
reported at positions 265-288, 213-372 and 352-360 was
exposed [18,31,32].
Knowing that the HN176 polypeptide is including the
region that has been suggested to be involved in the NA
activity [33], this activity was measured in total protein
extracts. We verified by two methods that the NA activ-
ity was present in the pcDNAHN176-transfected cells.
However, this NA activity was lower compared to the
activity in MuV-infected cells. Because the main recep-
tor binding domain of the MuV HN protein has been
proposed to be located at the same site as the neurami-
nidase activity [34], the HN176 polypeptide’s ability to
recognize sialic receptors on red cells was evaluated in
the construct-transfected cells using HA and HD reac-
tions. No HA was detected, but an HD reaction was
positive in the pcDNAHN176-transfected cells. This
result was unexpected because the construct did not
have a signal peptide to sort the HN176 polypeptide
into the cellular membrane. However, the specificity of
HD reaction was verified by blocking the reaction with
anti-MuV serum and, furthermore, by detecting the
amount of hemoglobin released from the cells using
Drabkin ‘s method. Nevertheless, the NA and HD activ-
ities in the pcDNAHN176-transfected cells were lower
than in MuV-infected cells, and none of these activities
were detected in the uninfected control or pcDNA3.1-
transfected cells. The low NA and HD activities were
probably due to an incomplete NA site in the HN176
polypeptide. However, these results support the proposal
that the pcDNAHN176-transfected cells were capable of
expressing the HN176 polypeptide in a correct folding
structure and exporting it to the surface such that it was
accessible to the erythrocytes or the antibodies to inhibit
the HD reaction. We do not know the mechanism by
which the peptide could be expressed on the cell sur-
face, but other groups using the same pcDNA3.1 vector
have reported that some proteins lacking the signal pep-
tide are sorted into the cellular membrane [35,36]. Some
of those proteins have shown the RXLXEQ motif, which
has been associated with ER exportation [37]. By bioin-
formatic analysis of our HN176 polypeptide, it seemed
to contain the RXLXEQ motif in positions 162-167
(data not shown).
Knowing that DNA vaccines can induce both humoral
and cell-mediated immune responses against many dif-
ferent antigens and that the immune response may
depend more on their ability to produce the mature
protein in an appropriate conformation than on whether
the protein is membrane-anchored or soluble and
whether it is targeted for secretion by conventional
mechanisms [38], we initially evaluated the immuno-
genic properties of the pcDNAHN176-construct by
immunization of rabbits using intradermal inoculation
into the ear pinnae. Usually, DNA vaccines are adminis-
tered through an intramuscular route; however, intra-
dermal inoculation has been a very successful route for
DNA plasmids [39]. Murine ear pinnae immunization
has shown to be an excellent site for initiating immune
responses with DNA vaccines [40]. Mechanism(s)
accounting for the superiority of the ear pinnae as a
vaccination site are ascribed to its unique immunologi-
cal features, which focus the concentration of processed
antigen in a restricted area that is connected with a
major draining lymph node. It is thought that the con-
centration of processed antigen results in an enhanced
stimulation of T lymphocytes by antigen-loaded dendri-
tic cells [40]. We found that the rabbit’s sera neutralized
the Urabe and the Jeryl Lynn MuV strains. Furthermore,
the sera neutralized both MuV strains to the same
extent, even though these strains belonged to a different
MuV genotype. The first one was the B genotype, and
the last one was the A genotype, indicating that immu-
nization with the pcDNAHN176-construct induced spe-
cific antibodies capable of neutralizing two different
MuV genotypes. Additionally, the antibodies induced by
the construct immunization specifically reacted with the
complete MuV HN protein and the HN176 polypeptide,
as observed by western blot assay (Figure 4A).
To confirm the immunogenic properties of the con-
struct, a MuV hamster intranasal infection was used.
Animals were split in six groups and intradermally
immunized in the ear pinnae with either the DNA-con-
struct or pcDNA3.1 vector. First, the body weight of the
animals was measured daily, and we found that the
MuV control (Group B), pcDNA3.1-immunized and
MuV challenged groups (Group E) presented a weight
loss, while the animals immunized with the
pcDNAHN176-construct and challenged with MuV
(Group F) showed a similar gain in weight to the non-
viral infected groups (Groups A, C, D) (Figure 4B). To
verify the viral infection, samples of different organs
were analyzed for MuV by isolation in Vero cells, and
we found that all of the samples from the viral control
group (Group B) were positive, but only two positive
samples were detected in the construct-immunized
group (Group F). Therefore, these results showed that
immunization with the DNA construct containing the
5 6 7n tr e g i o no ft h eH Ng e n eameliorated MuV infec-
tion, probably by reducing viral dissemination to differ-
ent organs.
To evaluate the effect of the pcDNAHN176-construct
vaccination on cellular responses, we measured
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antigens (Figure 4F). In the construct-immunized group
(Group F), there was a higher proliferation index when
the cells were stimulated with MuV than when using a
mitogen (PHA). However, the lymphoproliferation index
was very similar to the viral control group (B).
Spleen cells from group F showed that MuV-stimu-
lated cultures contained high levels of IL-2 and g-inter-
feron with little IL-4, indicating that intradermal DNA
vaccination in the ear pinnae area elicited Th1-like cyto-
kine responses. However, IL 5 was detected, suggesting
a mixed-phenotype or Th2-like response. Lower levels
of IFNg and IL2 were detected in the pcDNA3.1-immu-
nized and challenged hamsters (Group E). This unspeci-
fic induction by pcDNA3.1 immunization in hamsters
has been previously reported [35]. Plasmid DNA vac-
cines, when injected intramuscularly or intradermally,
induce a Th1 response due to the vector CpG motifs
that stimulate the production of IL-12, which favors the
activation of Th1 lymphocytes [41]. DNA vaccines have
been shown to induce antigen-specific IFN-g-secreting
Th1 cells, which are detectable in the spleen or lymph
nodes [42], and also generate Th2 or mixed Th1/Th2
type responses [42,43]. In this report, we found that the
pcDNAHN176-construct was capable of inducing both
the Th1 and Th2 responses, and the ear pinnae immu-
nization seemed to produced better results than intra-
muscular (IMI) immunization because the IMI did not
reduce the weight loss and MuV was detected in all of
the analyzed organs (data not shown).
Therefore, the pcDNAHN176-construct could be a
good candidate for use as a DNA vaccine. This proposal
is also supported by the bioinformatic analysis we car-
ried out with 81 strains of nine known different MuV
genotypes and 13 strains with unknown genotypes
deposited in GenBank [44], which confirmed that the
HN176 region is highly conserved among the different
MuV types.
Conclusions
The pcDNAHN176-construct expresses a polypeptide in
Vero cells that conserves the main biological properties
of the HN protein. The construct immunization in rab-
bits and hamsters was capable of inducing a specific
immune response against MuV. The results are very
encouraging for a MuV DNA vaccine, which could be
very useful against the different MuV genotypes. There-
fore, it is important to carry out more studies to evalu-
ate the pcDNAHN176-construct against more MuV
genotypes, determine how long the immune response
lasts and improve its immunogenic properties to obtain
a long-lasting immune response before it can be pro-
posed as a new MuV vaccine.
Methods
Selection and cloning of a region from the HN gene
The nucleotide sequences of the mump virus HN gene
were obtained from GenBank [44] (accession numbers:
X93178, X93179, X93180, X93181, X15284, X98875,
X98874, X93177, D86170) and translated in silico using
t h eE x P A S yP r o t e o m i c sS e r v e r[ 4 5 ] .N u c l e o t i d ea n d
amino acid sequences were aligned using ClustalW to
search for highly conserved regions among the different
MuV strains. The protein antigenic properties of the
protein were evaluated using the ANTHEPROT software
[46] and the antigenicity scale described by Parker et al.
[47]. We found 27 highly conserved regions and 30 anti-
genic regions, six of them represented the most anti-
genic segments.
Based on those analyses, a set of oligonucleotide pri-
mers (HN-sense 5′ CGCGGATCCAGCTGCTCAATTG-
CAACAGTCCCT 3′ and HN-antisense 5′ GGGGTA
CCGAGTTCATACGGCCACCAGCT 3′) was designed
to amplify the region from nucleotides 817 to 1383 of
the HN gene.
Virus, cells and vectors
The Urabe Am-9 mumps virus strain was grown in
chicken embryo fibroblast cell cultures using M-199
supplemented with 10% newborn calf serum and puri-
fied by the polyethylene glycol precipitation method.
Viral RNA was extracted with TRIzol (GIBCO BRL®)
according to manufacturer’s protocol, and reverse tran-
scribed into cDNA using 3 μgo fR N A ,1μlo ft h eH N
sense primer (200 μM), 6 μl of RT buffer (10×), 4 μlo f
DDT (0.1 M), 4 μlo fd N T P s( 1 0m M ) ,1μlo fR N a s i n
and 1 μl of RT (200 U/ml, Super Script). The reaction
was held at 42°C for 50 min.
Five μl of the RT product was PCR amplified using
the Taq PCR Core Kit (QIAGEN®) and the HN-sense
and HN-antisense primers at 92°C for 5 min, followed
by 30 cycles of 45 s at 94°C, 45 s at 66°C and 45 s at
72°C, with a final extension at 72°C for 7 min.
The PCR product was purified and directly cloned in
frame into the KpnIa n dBamHI sites of the pcDNA3.1
(+) expression vector (Invitrogen®). The integrity and
orientation of the construct (pcDNA-HN176) were veri-
fied by restriction analysis and automatically sequenced
using the dideoxynucleotide chain-termination method
[48].
Expression of the HN insert
Vero cells grown in M199 supplemented with 10% of
newborn calf serum were transfected with the
pcDNAHN176-construct or pcDNA3.1 using the Poly-
Fect Transfection Reagent (QIAGEN®) following the
manufacturer’s instructions. Transfected cells were
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RNA from transfected and non-transfected cells was
obtained using the TRIzol (GIBCO BRL®) method. Cel-
lular RNA (25 ng) was reverse transcribed using the
Sensiscript RT Kit (QIAGEN®), and the HN-antisense
primer and the RT product was PCR amplified using
the Taq PCR Core Kit (QIAGEN®) and both primers,
HN-sense and HN-antisense. The PCR conditions were
the same as described above. The PCR product was ana-
lyzed by 1% agarose gel electrophoresis followed by
staining with ethidium bromide.
Immunochemistry
Transfected Vero cells were grown on cover slips and
fixed with 4% paraformaldehyde at room temperature.
Cells were washed with PBS for 5 min and blocked with
albumin 1%-tween 20 (0.001%) overnight at 4°C. Then
the cells were washed again and incubated with a refer-
ence anti-mumps antibody (horse hyperimmune serum,
kindly donated by the Centers for Disease Control and
Prevention, (CDC, USA) at 4°C overnight. Following,
the cells were incubated with a biotinylated anti-horse
phosphatase alkaline antibody (Jackson Immuno
Research) for 2 h at room temperature. Finally, cells
were incubated with APPurple (Intergen®) for 15 min at
room temperature.
Immunofluorescence
Transfected cells were grown and fixed as describe
above, washed with PBS for 5 min and blocked with 1%
albumin overnight at 4°C. Then the cells were overnight
incubated with rabbit anti-MuV serum at 4°C, and after-
wards, incubated with an anti-rabbit fluorescent anti-
body (Jackson Immuno Research®) for 2 h at room
temperature. Finally, the cells were observed under a
fluorescent microscope.
In both immunoassays, Vero cells infected with MuV
at 0.2 MOI and incubated for 72 h were used as an HN
positive control.
Biological activities of the HN 176 polypeptide
Hemadsorption (HD) assay
The transfected Vero cells were grown in microplates.
Two days later, the cellular medium was removed, the
cells were washed with PBS and a suspension of 4% gui-
nea pig red cells was added to the cells for 1 h at 4°C.
The cells were extensively washed with PBS and
observed under an inverted microscope [25]. The
amount of bound red cells was calculated by measure-
ment the hemoglobin on the cells using the hemoglo-
bincyanide method described by Drabkin, 1935 [26].
The amount of hemoglobin found in the MuV-infected
cells was considered as 100%, and as proportional to the
amount of erythrocytes absorbed to the cells. The speci-
ficity of the HD assay was verified by HD inhibition
using the reference horse hyperimmune anti-MuV
serum. As a positive control for the HD and HDI assays,
Vero cells infected with MuV at 0.2 MOI and incubated
for 72 h were used.
Neuraminidase (NA) assay
A total cellular protein extract was obtained from the
transfected Vero cells, which was concentrated by cen-
trifugation and resuspended in PBS-triton 100 (0.01%)
in the presence of a protease inhibitor cocktail
(SIGMA). Proteins were precipitated overnight using
cold acetone at -20°C and pelleted at 12,000 × g.T h e
protein concentration was determined using Bradford’s
method [49], and neuraminidase activity was measured
by the dot assay using the synthetic substrate 2’-(4-
methylumbelliferyl)-a D-N-acetylneuraminic acid (MU-
NANA) according to the method described by Moncla
and Braham, [50]. Additionally, a spectrophotometric
assay was used. In both assays, the relative neuramini-
dase activity was expressed as a percentage of the NA
activity observed in similar extracts obtained from
MuV-infected cells.
Immunogenic properties
All animal experiments were carried under the supervi-
sion of the Institutional Bioethical Committee and the
Head of the animal house facilities.
Rabbit Immunization
Two eight-week old rabbits were immunized into the
pinnea area of the ear via intradermal injection using
100 μg of pcDNAHN176-construct DNA. Another two
rabbits were immunized with the pcDNA3.1 plasmid.
Eight days later, a second boost immunization was
applied in the same zone. As a positive control, a rabbit
was immunized with MuV in complete Freud adjuvant,
and a week later, a 2
nd boost with incomplete Freud
adjuvant was applied. At day twenty-three, the animals
were euthanized, and serum was collected and concen-
trated by precipitation with ammonium sulfate [51].
Sera were used for viral neutralization assays and wes-
tern blot analyses.
Neutralization assay
Two MuV strains, the Urabe and the Jeryl Lynn strains,
were used in the assay. The NT antibody titer was cal-
culated using Kärber’sf o r m u l aa n de x p r e s s e da st h e
50% neutralizing endpoint dilution of the serum.
Western Blot
To verify that the antibodies specifically recognized the
viral HN protein, cellular extract obtained from MuV-
Vero infected cells or pcDNAHN176 transfected cells
were separated by 16% SDS-PAGE. The proteins were
electrophoretically transferred onto nitrocellulose
membranes at 100 mA for 4 h. After washing the
membranes with distilled water, they were blocked
with PBS-Albumin (1%) overnight at 4°C. Rabbit serum
diluted 1:100 was added, followed by incubation
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Page 9 of 11overnight at 4°C. The bound antibodies were detected
by horseradish peroxidase-conjugated anti-rabbit IgG
(Zimed ®).
Hamster immunization and viral challenge
Five-week old hamsters used in the assays were divided
in six groups: Group A, animals without immunization
and without challenge; Group B, animals without immu-
nization and challenged with MuV (viral control group);
Group C, animals immunized with pcDNA3.1 without
challenge; Group D, animals immunized with
pcDNAHN176 without challenge; Group E, animals
immunized with pcDNA3.1 and challenged with MuV;
and Group F, animals immunized with pcDNAHN176-
construct and challenged with MuV.
Hamsters were immunized intradermically into the ear
pinnae using 100 μg of DNA from the pcDNAHN176-
construct or pcDNA3.1 plasmid. Seven days later, a sec-
ond boost immunization was applied in the same zone.
A week after the last immunization, the hamsters were
intranasally infected with 100 μlo f1 0
6.8 TCID50/ml
Urabe AM9 MuV. The animals were euthanized four-
teen days after the viral challenge to obtain serum, liver,
pancreas, sexual gonads, lungs, trachea and brain. The
organs were macerated and used to infect Vero cells.
Five days after infection, an HD assay was realized.
The spleen cells were used for a lymphoproliferation
assays. Briefly, 5 × 10
5 spleen cells were cultivated in
96-well dishes and stimulated with 5 × 10
5 TCID50/ml
of MuV or 3 μg of PHA. Seventy-two hours after stimu-
lation, the cell proliferation was measured using the
MTT method.
Another sample of spleen cells was stimulated with
MuV as described above and incubated for 72 hours.
The supernatant was used to measure several cytokines
using the Mouse Th1/Th2 Six-Plex Antibody Bead Kit
Luminex System (Invitrogen ®) according to the manu-
facturer’s instructions. Sera of the animals were used to
measure the neutralizing antibodies.
All of the animals were observed and weighed every
day.
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